Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis

International Journal of Molecular Sciences

Volumn 9, Issue 11, 2008, Pages 2194-2204

  Gari, Mamdooh ^a   Abuzenadah, Adel ^a   Chaudhary, Adeel ^a   Al Qahtani, Mohammed ^a   Banni, Huda ^a   Ahmad, Waseem ^a   Al Sayes, Fatin ^b   Lary, Sahira ^a   Damanhouri, Ghazi ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b King Abdulaziz University   (Saudi Arabia)

Author keywords

AML; Flt3; ITD; CSGE; Mutational analysis

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DNA SEQUENCE; EXON; GEL ELECTROPHORESIS; GENE AMPLIFICATION; GENE MUTATION; ONCOGENE; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 56449090547     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9112194     Document Type: Article

References (38)

1. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
2. Matthews, W.; Jordan, C.T.; Wiegand, G.W.; Pardoll, D.; Lemischka, I.R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991, 65, 1143-1152.
3. Rosnet, O.; Schiff, C.; Pébusque, M.J.; Marchetto, S.; Tonnelle, C.; Toiron, Y.; Birg, F. Birnbaum, D. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993, 82, 1110-1119.
4. Yarden, Y.; Ullrich, A. Growth factor receptor tyrosine kinase. Annu. Rev. Biochem. 1988, 57, 443-478.
5. Abu-Duhier, F.M.; Goodeve, A.C.; Wilson, G.A.; Care, R.S.; Peake, I.R.; Reilly, J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 2001, 113, 983-988.
6. Birg, E.; Courcoul, M.; Rosnet, O.; Bardin, F.; Pebusque, M.J.; Marchetto, S.; Tabilio, A.; Mannoni, P.; Birnbaum, D. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992, 80, 2584-2593.
7. Meierhoff, G.; Dehmel, U.; Gruss, H.J.; Rosnet, O.; Birnhaum, D.; Quentmeier, H.; Dirks, W.; Drexler, H.G. Expression of FLT3 receptor and FLT-3 ligand in human leukemia-lymphoma cell lines. Leukemia 1995, 9, 1368-1372.
8. Drexler, H.G. Expression of FLT3 receptor and response of to FLT3 ligand by leukemic cells. Leukemia, 1996, 10, 588-599.
9. Ihle, J.N; Witthuhn, B.A.; Quelle, F.W.; Yamamoto, K.; Silvennoinen, O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 1995, 13, 369-398.
10. Kelly, L.M.; Kutok, J.L.; Williams, I.R.; Boulton, C.L.; Amaral, S.M.; Curley, D.P.; Ley, T.J.; Gilliland, D.G. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. USA 2002, 99, 8283-8288.
11. Kelly, L.M.; Liu, Q.; Kutok, J.L.; Williams, I.R.; Boulton, C.L.; Gilliland, D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002, 99, 310-318.
12. Zhao, M.; Kiyoi, H.; Yamamoto, Y.; Ito, M.; Towatari, M.; Omura, S.; Kitamura, T.; Ueda, R.; Saito, H.; Naoe, T. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia 2000, 14, 374-378.
13. Tse, K.F.; Novelli, E.; Civin, C.I.; Bohmer, F.D.; Small, D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001, 15, 1001-1010.
14. Levis, M.; Tse, K.F.; Smith, B.D.; Garrett, E.; Small, D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001, 98, 885-887.
15. Weisberg, E.; Boulton, C.; Kelly, L.M.; Manley, P.; Fabbro, D.; Meyer, T.; Gilliland, D.G.; Griffin, J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1, 433-443.
16. O'Farrell, A.M.; Foran, J.M.; Fiedler, W.; Serve, H.; Paquette, R.L.; Cooper, M.A.; Yuen, H.A.; Louie, S.G.; Kim, H.; Nicholas, S.; Heinrich, M.C.; Berdel, W.E.; Bello, C.; Jacobs, M.; Scigalla, P.; Manning, W.C.; Kelsey, S.; Cherrington, J.M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003, 9, 5465-5476.
17. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O.G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A.M.; Jacobs, M.; Brega, N.M.; Scigalla, P.; Hossfeld, D.K.; Berdel, W.E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
18. DeAngelo, D.J.; Stone, R.M.; Heaney, M.L.; Nimer, S.D.; Paquette, R.L.; Klisovic, R.B.; Caligiuri, M.A.; Cooper, M.R.; Lecerf, J.M.; Karol, M.D.; Sheng, S.; Holford, N.; Curtin, P.T.; Druker, B.J.; Heinrich, M.C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108, 3674-3681.
19. Stone, R.M.; de Angelo, J.; Galinsky, I.; Estey, E.; Klimek, V.; Grandin, W.; Lebwohl, D.; Yap, A.; Cohen, P.; Fox, E.; Neuberg, D.; Clark, J.; Gilliland, D.G.; Griffin, J.D. PKC 412 FLT3 inhibitor therapy in AML: Results of a phase II trial. Ann. Hematol. 2004, 83, 89-90.
20. Fenski, R.; Flesch, K.; Serve, S.; Mizuki, M.; Oelmann, E.; Kratz, A.; Kienast, J.; Leo, R.; Schwartz, S.; Berdel, W.E.; Serve, H. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 2000, 108, 322-330.
21. Kiyoi, H.; Towatari, M.; Yokota, S.; Hamaguchi, M.; Ohno, R.; Saito, H.; Naoe, T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12, 1333-1337.
22. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; Akiyama, H.; Saito, K.; Nishimura, M.; Motoji, T.; Shinagawa, K.; Takeshita, A.; Saito, H.; Ueda, R.; Ohno, R.; Naoe, T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97, 2434-2439.
23. Xu, F.; Taki, T.; Yang, H.W.; Hanada, R.; Hongo, T.; Ohnishi, H.; Kobayashi, M.; Bessho, F.; Yanagisawa, M.; Hayashi, Y. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 1999, 105, 155-162.
24. Abu, D.; Goodeve, A.C.; Wilson, G.A.; Gari, M.A.; Peake, I.R.; Rees, D.C.; Vandenberghe, E.A.; Winship, P.R.; Reilly, J.T. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 2000, 111, 190-195.
25. Horiike, S.; Yokota, S.; Nakao, M.; Iwai, T.; Sasai, Y.; Kaneko, H.; Taniwaki, M.; Kashima, K.; Fujii, H.; Abe, T.; Misawa, S. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997, 11, 1442-1446.
26. Kiyoi, H.; Naoe, T.; Nakano, Y.; Yokota, S.; Minami, S.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Jinnai, I.; Shimazaki, C.; Akiyama, H.; Saito, K.; Oh, H.; Motoji, T.; Omoto, E.; Saito, H.; Ohno, R.; Ueda, R. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93, 3074-3080.
27. Yokota, S.; Kiyoi, H.; Nakao, M.; Iwai, T.; Misawa, S.; Okuda, T.; Sonoda, Y.; Abe, T.; Kahsima, K.; Matsuo, Y.; Naoe, T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997, 11, 1605-1609.
28. Wang, L.; Lin, D.; Zhang, X.; Chen, S.; Wang, M.; Wang, J. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk. Res. 2005, 29, 1393-1398.
29. Auewarakul, C.U.; Sritana, N.; Limwongse, C.; Thongnoppakhun, W.; Yenchitsomanus, P.T. Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet. Cytogenet. 2005, 162, 127-134.
30. Thiede, C.; Steudel, C.; Mohr, B.; Schaich, M.; Schäkel, U.; Platzbecker, U.; Wermke, M.; Bornhäuser, M.; Ritter, M.; Neubauer, A.; Ehninger, G.; Illmer, T. Analysis of FLT3 activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99, 4326-4335.
31. Ganguly, A. An update on conformation sensitive gel electrophoresis. Hum. Mutat. 2002, 19, 334-342.
32. Williams, I.J.; Abuzenadah, A.; Winship, P.R.; Preston, F.E.; Dolan, G.; Wright, J.; Peake, I.R.; Goodeve, A.C. Precise carrier diagnosis in families with haemophilia A: Use of conformational sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb. Haemost. 1998, 79, 723-726.
33. Goodeve, A.C.; Williams, I.; Bray, G.L.; Peake, I.R. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb. Haemost. 2000, 83, 844-848.
34. Hashemi Soteh, M.; Peake, I.R.; Marsden, L.; Anson, J.; Batlle, J.; Meyer, D.; Fressinaud, E.; Mazurier, C.; Goudemand, J.; Eikenboom, J.; Goodeve, A. MCMDM-1VWD Study Group. Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haematologica 2007, 92, 550-553.
35. Hinks, J.L.; Winship, P.R.; Makris, M.; Preston, F.E.; Peake, I.R.; Goodeve, A.C. Rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. Br. J. Haematol. 1999, 104, 915-918.
36. Gari, M.A; Abuzenadah, A.M.; Chaudhary, A.G.; Al-Qahtani, M.H.; Al-Says, F.M.; Dmanhouri, G. Pilot study of DNA extraction from archival unstained bone marrow slides: comparison of three rapid methods. Af J. Biotech. 2006, 5, 532-535.
37. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C. Proposal for the classification of the acute leukaemias. French American British (FAB) cooperative group. Br. J. Haematol. 1976, 33, 451-458.
38. Grimwade, D.; Walker, H.; Oliver, F.; Wheatley, K.; Harrison, C.; Harrison, G.; Rees, J.; Hann, J.; Hann, I.; Stevens, R.; Burnett, A.; Goldstone, A. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92, 2322-2333.